Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRN23 in Pediatric Epidermal Nevus Syndrome
NCT04320316Phase 4Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Jul 2020
- Primary completion
- Jul 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of burosumab in epidermal nevus syndrome (ENS), hypophosphatemic rickets (HR), sponsored by University of Alabama at Birmingham. Started Jul 2020; status: completed.
02
Drugs
burosumab
03
Conditions
epidermal nevus syndrome (ENS)hypophosphatemic rickets (HR)
Beyond the preview
Go deeper on NCT04320316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04320316.